1. Home
  2. PEB vs PHVS Comparison

PEB vs PHVS Comparison

Compare PEB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pebblebrook Hotel Trust of Beneficial Interest

PEB

Pebblebrook Hotel Trust of Beneficial Interest

HOLD

Current Price

$18.35

Market Cap

2.1B

Sector

Real Estate

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$37.23

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEB
PHVS
Founded
2009
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.4B
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
PEB
PHVS
Price
$18.35
$37.23
Analyst Decision
Hold
Buy
Analyst Count
11
11
Target Price
$13.30
$41.82
AVG Volume (30 Days)
2.0M
558.5K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
0.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,475,544,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.53
N/A
52 Week Low
$9.99
$20.65
52 Week High
$19.93
$38.13

Technical Indicators

Market Signals
Indicator
PEB
PHVS
Relative Strength Index (RSI) 48.62 63.27
Support Level $18.35 $24.73
Resistance Level $19.73 N/A
Average True Range (ATR) 0.51 1.78
MACD -0.01 0.26
Stochastic Oscillator 57.28 88.50

Price Performance

Historical Comparison
PEB
PHVS

About PEB Pebblebrook Hotel Trust of Beneficial Interest

Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: